Allianz’s Vertex Pharmaceuticals VRTX Stock Holding History

Allianz’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.9M	Hold	23,921	–	–	0.13%	97
2026 Q1	$10.7M	Sell	23,921 -1,260	-5%	-$588K	0.12%	104
2025 Q4	$11.4M	Buy	25,181 +1,260	+5%	+$543K	0.15%	84
2025 Q3	$9.37M	Sell	23,921 -14	-0.1%	-$5.85K	0.2%	90
2025 Q2	$10.7M	Sell	23,935 -12	-0.1%	-$5.53K	0.25%	77
2025 Q1	$11.6M	Sell	23,947 -54	-0.2%	-$25.2K	0.31%	66
2024 Q4	$9.58M	Sell	24,001 -2,088	-8%	-$968K	0.25%	81
2024 Q3	$12.1M	Buy	26,089 +1,777	+7%	+$854K	0.33%	66
2024 Q2	$11.4M	Sell	24,312 -1,660	-6%	-$721K	0.33%	59
2024 Q1	$10.9M	Buy	+25,972	New	+$11M	0.34%	66

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Allianz's VRTX Position: Q2 2026 in Review

Allianz held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 23,921 shares worth $11.9M. The position accounts for 0.13% of the portfolio, ranked #97.

Allianz first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $12.1M in Q3 2024. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Allianz held 23,921 shares of Vertex Pharmaceuticals worth $11.9M as of Q2 2026.
Allianz left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.13% of Allianz's portfolio in Q2 2026, its #97 holding.
Allianz first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Allianz's Vertex Pharmaceuticals position peaked at $12.1M in Q3 2024.
1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Allianz's 13F filing for Q2 2026, filed 10 Aug 2026.